China’s regulator has approved the country’s first neuroimplant for commercial use. The invasive brain-computer interface (BCI) device aids patients with paralysis in partially regaining control over hand movements, reports Bloomberg.
The National Medical Products Administration granted the market release approval. The technology was developed by Shanghai-based Neuracle Technology, a company specializing in neurointerfaces.
The startup’s BCI system was tested on 36 patients and includes:
- sensors implanted on the cerebral cortex;
- a robotic glove;
- surgical instruments;
- a neural signal decoding algorithm;
- software for verification and clinical use.
The technology is intended for adult patients with partial paralysis due to spinal cord injury. During trials, the implant helped participants regain the ability to grasp and hold objects.
However, the product is applicable only to individuals who retain some functionality in the upper arm. This limitation is due to fewer channels and limited signal recognition capabilities compared to more advanced competitors.
Bloomberg described Neuracle’s commercial approval as a significant milestone for the rapidly evolving neurointerface market. Chinese startups are eager to outpace Western companies, including Neuralink by Elon Musk, Synchron, Paradromics, and Merge Labs, in commercializing the technology.
Experts noted that the Chinese regulator’s decision could accelerate the development of similar market solutions.
Beijing views neurointerfaces as a promising high-tech sector, providing strong government support to startups and aiming to establish a full-fledged industry in the coming years. Authorities have promised to simplify regulatory checks and implement a cost reimbursement mechanism for product market entry.
Earlier, people will need to enhance their intelligence by implanting devices in their brains to remain relevant amid the rapid development of AI technologies, according to Tether CEO Paolo Ardoino.
